Danaher seals deal for Beckman Coulter
Sales negotiations between Danaher and Beckman Coulter have led to a deal
Danaher Corporation is to enter into a merger agreement with Beckman Coulter following successful sales negotiations and meetings between the firm, it has been revealed.
Danaher announced the $6.8 billion deal today (February 7th) and president and chief executive officer of the firm H. Lawrence Culp Jnr praised Beckman Coulter's iconic status and sound market position.
"Beckman provides an excellent complement to our existing Life Sciences and Diagnostics businesses," he added.
Beckman Coulter will now take its place in Danaher's Life Sciences and Diagnostic's arm alongside firms including AB Sciex, Molecular Devices, Radiometer and Leica.
Danaher will acquire the firm by purchasing all of its outstanding shares of common stock at a cost of $83.50 per share.
Danaher Corporation works in a number of sectors and has seven strategic platforms, including medical technologies, professional instrumentation, tools and components and industrial technologies. At the end of 2010, it has some 48,000 employees.